LYG-202 augments tumor necrosis factor-α-induced apoptosis via attenuating casein kinase 2-dependent nuclear factor-κB pathway in HepG2 cells

Molecular Pharmacology

Volumn 82, Issue 5, 2012, Pages 958-971

  Chen, Fei Hong ^a   Lu, Na ^a   Zhang, Hai Wei ^a   Zhao, Li ^a   He, Li Cheng ^a   Sun, Hao Peng ^a   You, Qi Dong ^b   Li, Zhi Yu ^a   Guo, Qing Long ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Center for Pharmacodynamics Research and Evaluation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; CASPASE 3; CASPASE 8; CASPASE 9; CX 4945; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; LYG 202; NAPHTHYRIDINE 8 CARBOXYLATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CANCER COMBINATION CHEMOTHERAPY; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASEIN KINASE II; CASPASES; CELL NUCLEUS; CELL PROLIFERATION; DRUG SYNERGISM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLAVONES; GENES, REPORTER; HEP G2 CELLS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; LUCIFERASES; MALE; MICE; MOLECULAR DOCKING SIMULATION; NF-KAPPA B; PHOSPHORYLATION; PIPERAZINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867820107     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079848     Document Type: Article

References (59)

1. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745-756.
2. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361-371.
3. Bird GL, Sheron N, Goka AK, Alexander GJ, and Williams RS (1990) Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 112:917-920. (Pubitemid 20193676)
4. Böcker W, Docheva D, Prall WC, Egea V, Pappou E, Rossmann O, Popov C, Mutschler W, Ries C, and Schieker M (2008) IKK-2 is required for TNF-α-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med 86:1183-1192.
5. Bosman FT, Visser BC, and van Oeveren J (1996) Apoptosis: pathophysiology of programmed cell death. Pathol Res Pract 192:676-683. (Pubitemid 26302242)
6. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, and Kroemer G (2006) Targeting NF-κB in hematologic malignancies. Cell Death Differ 13:748-758.
7. Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, Lu H, Korman V, Unger G, Ahmed K, et al. (2010) CK2 modulation of NF-κB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules. Clin Cancer Res 16:2295-2307.
8. Cao SS and Zhen YS (1989) Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 24:181-186.
9. 2 cells. Cancer Lett 296:96-105.
10. Chen Y, Lu N, Ling Y, Wang L, You Q, Li Z, and Guo Q (2010b) LYG-202, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo. J Pharmacol Sci 112:37-45.
11. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681.
12. Davies SP, ReddyH, CaivanoM, and Cohen P (2000) Specificity andmechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (Pt 1):95-105.
13. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, and Eggermont AM (2000) Tumour necrosis factor α increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82:1000-1003.
14. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, et al. (2008) Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68:1443-1450. (Pubitemid 351346852)
15. Farah M, Parhar K, Moussavi M, Eivemark S, and Salh B (2003) 5,6-Dichloro-ribifuranosylbenzimidazole- and apigenin-induced sensitization of colon cancer cells to TNF-α-mediated apoptosis. Am J Physiol Gastrointest Liver Physiol 285:G919-G928. (Pubitemid 37310071)
16. Goossens V, Grooten J, De Vos K, and Fiers W (1995) Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 92:8115-8119.
17. Hayden MS and Ghosh S (2004) Signaling to NF-κB. Genes Dev 18:2195-2224.
18. van Horssen R, Ten Hagen TL, and Eggermont AM (2006) TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11:397-408.
19. Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18:621-663. (Pubitemid 30365393)
20. Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K, et al. (2007) Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 47:546-555. (Pubitemid 47331746)
21. Lejeune FJ (2002) Clinical use of TNF revisited: improving penetration of anticancer agents by increasing vascular permeability. J Clin Invest 110:433-435.
22. Li H, Zhu H, Xu CJ, and Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501. (Pubitemid 28391865)
23. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369 (Pt 1):1-15.
24. 1/S cell cycle arrest and apoptosis via p53 and p21(WAF1/Cip1) expression. Biochem Cell Biol 89:287-298.
25. Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, Herceg Z, Wang ZQ, and Schulze-Osthoff K (2002) Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell 13:978-988. (Pubitemid 34250359)
26. Lu Z, Lu N, Li C, Li F, Zhao K, Lin B, and Guo Q (2012) Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 209:211-220.
27. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, and Eggermont AM (1996) Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 83:551-555. (Pubitemid 26120788)
28. Middleton E Jr, Kandaswami C, and Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751.
29. Miró F, Lelong JC, Pancetti F, Roher N, Duthu A, Plana M, Bourdon JC, Bachs O, May E, and Itarte E (1999) Tumour suppressor protein p53 released by nuclease digestion increases at the onset of rat liver regeneration. J Hepatol 31:306-314. (Pubitemid 29349758)
30. Mocellin S, Rossi CR, Pilati P, and Nitti D (2005) Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35-53. (Pubitemid 40279116)
31. Nakamura N, Hayasaka S, Zhang XY, Nagaki Y, Matsumoto M, Hayasaka Y, and Terasawa K (2003) Effects of baicalin, baicalein, and wogonin on interleukin-6 and interleukin-8 expression, and nuclear factor-κB binding activities induced by interleukin-1beta in human retinal pigment epithelial cell line. Exp Eye Res 77:195-202. (Pubitemid 36842811)
32. Orlowski RZ and Baldwin AS, Jr. (2002) NF-κB as a therapeutic target in cancer. Trends Mol Med 8:385-389.
33. Perez D and White E (2000) TNF-α signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K. Mol Cell 6:53-63.
34. Pfeffer K (2003) Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14:185-191.
35. Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, et al. (2011) Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem 54:635-654.
36. Pilati P, Rossi CR, and Mocellin S (2008) Strategies to enhance the anticancer potential of TNF. Front Biosci 13:3181-3193. (Pubitemid 351589229)
37. Prudent R, Sautel CF, and Cochet C (2010) Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2. Biochim Biophys Acta 1804:493-498.
38. Schmid JA and Birbach A (2008) IκB kinase β (IKKβ/IKK2/IKBKB) - a key molecule in signaling to the transcription factor NF-κB. Cytokine Growth Factor Rev 19:157-165. (Pubitemid 351382281)
39. Schoonbroodt S, Ferreira V, Best-Belpomme M, Boelaert JR, Legrand-Poels S, Korner M, and Piette J (2000) Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of IκB α in NF-κB activation by an oxidative stress. J Immunol 164:4292-4300. (Pubitemid 30215091)
40. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, and Fiers W (1992) Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem 267:5317-5323.
41. Sethi G, Sung B, and Aggarwal BB (2008) TNF: a master switch for inflammation to cancer. Front Biosci 13:5094-5107. (Pubitemid 351599660)
42. Seynhaeve AL, de Wilt JH, van Tiel ST, Eggermont AM, and ten Hagen TL (2002) Isolated limb perfusion with actinomycin D and TNF-α results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer 86:1174-1179. (Pubitemid 34438093)
43. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, et al. (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70:10288-10298.
44. Sugimoto K, Shiraki K, Ito T, Fujikawa K, Takase K, Tameda Y, Moriyama M, and Nakano T (1999) Expression of functional CD40 in human hepatocellular carcinoma. Hepatology 30:920-926. (Pubitemid 29458280)
45. Suk K, Lee H, Kang SS, Cho GJ, and Choi WS (2003) Flavonoid baicalein attenuates activation-induced cell death of brain microglia. J Pharmacol Exp Ther 305:638-645. (Pubitemid 36459181)
46. Sun HP, Zhu J, Chen FH, and You QD (2010) Structure-based pharmacophore modeling from multicomplex: a comprehensive pharmacophore generation of protein kinase CK2 and virtual screening based on it for novel inhibitors. Mol Informat 30:579-592.
47. Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, Liu M, and Aggarwal BB (2008) Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-κB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-κBα kinase, leading to potentiation of apoptosis. Blood 111:4880-4891.
48. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, and Ahmed K (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 36:187-195.
49. Uzzo RG, Leavis P, Hatch W, Gabai VL, Dulin N, Zvartau N, and Kolenko VM (2002) Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 8:3579-3583. (Pubitemid 35340736)
50. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, and ten Hagen TL (2000) TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 82:973-980. (Pubitemid 30085254)
51. van Horssen R, Ten Hagen TL, and Eggermont AM (2006) TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11:397-408.
52. Wallach D (1997) Cell death induction by TNF: a matter of self control. Trends Biochem Sci 22:107-109.
53. Wang X, Zhang J, and Xu T (2008) Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur J Pharmacol 579:66-73.
54. Yu M, Yeh J, and Van Waes C (2006) Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 66:6722-6731. (Pubitemid 44085630)
55. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, and Karin M (1997) The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 91:243-252. (Pubitemid 27456391)
56. Zeng S, Liu W, Nie FF, Zhao Q, Rong JJ, Wang J, Tao L, Qi Q, Lu N, Li ZY, et al. (2009) LYG-202, a new flavonoid with a piperazine substitution, shows antitumor effects in vivo and in vitro. Biochem Biophys Res Commun 385:551-556.
57. Zhang LB, Qiang L, Chen FH, Wu T, Rong JJ, Zhao Q, Zou MJ, Yang Z, You QD, Li ZY, et al. (2010) DHF-18, a new synthetic flavonoid, induced a mitochondrial-mediated apoptosis of hepatocarcinoma cells in vivo and in vitro. Eur J Pharmacol 651:33-40.
58. Zhao L, Chen Z, Wang J, Yang L, Zhao Q, Wang J, Qi Q, Mu R, You QD, and Guo QL (2010) Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol 65:481-489.
59. Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, and Yu XD (2011) Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer 10:104.